

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 May 2024 (23.05.2024)



(10) International Publication Number
WO 2024/105610 A1

(51) International Patent Classification:

A61K 31/495 (2006.01) *A61K 31/704* (2006.01)
A61K 31/522 (2006.01) *A61K 31/7048* (2006.01)
A61K 31/4745 (2006.01) *A61K 45/06* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
A61K 31/555 (2006.01)

(21) International Application Number:

PCT/IB2023/061593

(22) International Filing Date:

16 November 2023 (16.11.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/384,313 18 November 2022 (18.11.2022) US
63/486,206 21 February 2023 (21.02.2023) US
63/508,015 14 June 2023 (14.06.2023) US
63/582,920 15 September 2023 (15.09.2023) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **CORTES-CROS, Marta**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **FERRETTI, Stephane**; c/o Novartis Pharma AG, NIBR Klybeck Novartis Institutes for Biomed. Research, Klybeckstrasse 141, 4057 Basel (CH). **HAMON, Jacques**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **HINRICHS, Juergen Hans-Hermann**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **JACO, Isabel Cristina**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **BLUM-KALLERT, Sandra**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **LABORDE, Laurent**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **MOEBITZ, Henrik**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **SCHOEPFER, Joseph**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **STRANG, Ross**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **DE KANTER, Ruben**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **ANDRAOS-REY, Rita**; c/o Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH).

MOSCHETTA, Michele; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PHARMACEUTICAL COMBINATIONS AND USES THEREOF



(57) Abstract: The present invention provides a pharmaceutical combination comprising a WRN inhibitor in combination with at least one additional therapeutically active agent. It also provides a method of treating cancer, involving administering to a subject in need thereof the WRN inhibitor in combination with the at least one additional therapeutically active agent. For example, the WRN inhibitor compound, or a pharmaceutically acceptable salt thereof, is of formula (I): wherein R₁, R₂, R₃, R₄, R₅, R₂₆, R₂₇, y, R, M, W, L, V, T, Y, J, K and A are as described herein.

WO 2024/105610 A1